ANSWER 50 OF 89 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 03 May 1999
GI



I

AB Compds. represented by general formula (I) or salts thereof, (wherein n is an integer of 2 or 3; R represents a straight-chain or branched saturated alkyl group having 4 or 5 carbon atoms, a cyclopentyl group, a cyclohexyl group or the like; Y represents a hydroxyl or amino group; A represents a hydrogen atom, a hydroxyl, methoxy, nitro group or the like; Q represents a hydrogen atom or a hydroxyl or methoxy group) are claimed and prepared They can be formulated to give pharmaceutical compns. that are effective as prophylactic or therapeutic agents for allergic diseases associated with IgE (IgE) production inhibitors or IgE antibodies, e.g. bronchial asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis. Thus, Me 3-(2-hydroxy-1,1'-biphenyl-5-yl)propionate was alkylated by Bu iodide in the presence of K2CO3 in DMF at room temperature for 16 h followed by saponification in a mixture of 2 N aqueous NaOH and MeOH and acidification to give 3-(2-butoxy-1,1'-biphenyl-5-yl)propionic acid (II). II p.o. in vivo inhibited 72.3% IgE production in mice sensitized by egg white albumin.

ACCESSION NUMBER: 1999:271327 HCAPLUS <<LOGINID::20070820>>
DOCUMENT NUMBER: 130:281874
TITLE: Preparation of biphenyl-5-alkanoic acid derivatives as IgE antibody production inhibitors
INVENTOR(S): Shoda, Motoshi; Itoh, Hiromichi
PATENT ASSIGNEE(S): Asahi Kasei Kogyo Kabushiki Kaisha, Japan
SOURCE: PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9919291	A1	19990422	WO 1998-JP4456	19981002

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,

	CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2304713		A1	19990422	CA 1998-2304713		19981002
CA 2304713		C	20030610			
AU 9892824		A	19990503	AU 1998-92824		19981002
AU 735737		B2	20010712			
EP 1024130		A1	20000802	EP 1998-945584		19981002
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
CN 1103332		B	20030319	CN 1998-810235		19981002
US 6376546		B1	20020423	US 2000-509683		20000608
PRIORITY APPLN. INFO.:				JP 1997-280814	A	19971014
				WO 1998-JP4456	W	19981002

OTHER SOURCE(S): MARPAT 130:281874

IT 222627-02-3P, 3-(2-(Carboxymethoxy)-1,1'-biphenyl-5-yl)propionic acid 222627-38-5P, 4-(2-(Carboxymethoxy)-1,1'-biphenyl-5-yl)butyric acid
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biphenylalkanoic acid derivs. as IgE antibody production inhibitors for treatment and preparation of allergic diseases)

RN 222627-02-3 HCAPLUS

CN [1,1'-Biphenyl]-3-propanoic acid, 6-(carboxymethoxy)- (9CI) (CA INDEX NAME)



RN 222627-38-5 HCAPLUS

CN [1,1'-Biphenyl]-3-butanoic acid, 6-(carboxymethoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT